Edelfosine-induced metabolic changes in cancer cells that precede the overproduction of reactive oxygen species and apoptosis

dc.contributor.author
Selivanov, Vitaly
dc.contributor.author
Vizan Arroyo, José Luis
dc.contributor.author
Mollinedo García, Faustino
dc.contributor.author
Fan, Teresa W.
dc.contributor.author
Lee, Paul Wai Nang
dc.contributor.author
Cascante i Serratosa, Marta
dc.date.issued
2010-11-19T12:05:34Z
dc.date.issued
2010-11-19T12:05:34Z
dc.date.issued
2010-10-06
dc.identifier
1752-0509
dc.identifier
https://hdl.handle.net/2445/14482
dc.identifier
584363
dc.identifier
20925932
dc.description.abstract
Background: Metabolic flux profiling based on the analysis of distribution of stable isotope tracer in metabolites is an important method widely used in cancer research to understand the regulation of cell metabolism and elaborate new therapeutic strategies. Recently, we developed software Isodyn, which extends the methodology of kinetic modeling to the analysis of isotopic isomer distribution for the evaluation of cellular metabolic flux profile under relevant conditions. This tool can be applied to reveal the metabolic effect of proapoptotic drug edelfosine in leukemia Jurkat cell line, uncovering the mechanisms of induction of apoptosis in cancer cells. Results: The study of 13C distribution of Jukat cells exposed to low edelfosine concentration, which induces apoptosis in ¿5% of cells, revealed metabolic changes previous to the development of apoptotic program. Specifically, it was found that low dose of edelfosine stimulates the TCA cycle. These metabolic perturbations were coupled with an increase of nucleic acid synthesis de novo, which indicates acceleration of biosynthetic and reparative processes. The further increase of the TCA cycle fluxes, when higher doses of drug applied, eventually enhance reactive oxygen species (ROS) production and trigger apoptotic program. Conclusion: The application of Isodyn to the analysis of mechanism of edelfosine-induced apoptosis revealed primary drug-induced metabolic changes, which are important for the subsequent initiation of apoptotic program. Initiation of such metabolic changes could be exploited in anticancer therapy.
dc.format
11 p.
dc.format
application/pdf
dc.format
text/plain
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
BioMed Central
dc.relation
Reproducció del document publicat a http://dx.doi.org/10.1186/1752-0509-4-135
dc.relation
BMC Systems Biology, 2010, 4:135
dc.relation
http://dx.doi.org/10.1186/1752-0509-4-135
dc.relation
info:eu-repo/grantAgreement/EC/FP7/202013/EU//DIAPREPP
dc.relation
info:eu-repo/grantAgreement/EC/FP7/222639/EU//ETHERPATHS
dc.rights
cc-by (c) Selivanov et al., 2010
dc.rights
http://creativecommons.org/licenses/by/2.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Institut de Biomedicina (IBUB))
dc.subject
Càncer
dc.subject
Metabolisme cel·lular
dc.subject
Cancer
dc.subject
Cell metabolism
dc.title
Edelfosine-induced metabolic changes in cancer cells that precede the overproduction of reactive oxygen species and apoptosis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.